齐拉西酮与奎硫平对女性首发精神分裂症患者体质量的影响.docVIP

精品论文 参考文献 齐拉西酮与奎硫平对女性首发精神分裂症患者体质量的影响 彭红星 黄兴东 　　(重庆市三峡民康医院 重庆忠县 404300) 　　【摘要】 目的：探讨齐拉西酮与奎硫平对女性首发精神分裂症患者体质量、腹围及体质量指数（BMI）的影响。方法：将63例女性首发精神分裂症患者随机分为齐拉西酮合并奎硫平组31例（试验组）及单用奎硫平组32例（对照组）。在治疗前及治疗8周，用阳性与阴性症状量表（PANSS）评定疗效，并进行体质量、腹围、BMI的测定。结果：治疗8周后两组PANSS评分差异无统计学意义（t=1.351，Pgt;0.05）；试验组治疗后腹围值增加明显（t=2.574，Plt;0.05），对照组体质量、腹围、BMI值均增加明显（Plt;0.05）；试验组治疗前后体质量、腹围、BMI增加值均较对照组小（Plt;0.05）。结论：联用齐拉西酮能够明显减轻奎硫平对女性首发精神分裂症患者的体质量增加的影响 　　【关键词】齐拉西酮 奎硫平 体质量 精神分裂症 女性 　　【中图分类号】R453 【文献标识码】A 【文章编号】2095-1752（2014）03-0009-02 　　Effects of ziprasidone and quetiapine on the body mass of female patients with first-episode schizophrenia PENG Hong-xing, HUANG Xing-dong. Three Gorges MinKang Hospital of Chongqing, Zhongxian 404300 　　【Abstract】Objective : To explore the effects of ziprasidone and quetiapine on the body mass,abdominal girth and body mass index (BMI) of female patients with first-episode schizophrenia. Method: Sixty-three female patients with first-episode schizophrenia were randomlized divided into two groups. The trial group were treated with ziprasidone combined with quetiapine group and the control group were treated with quetiapine . Clinical efficacies were assessed with positive and negative symptom scale (PANSS) and the body mass , abdominal circumference and BMI in patients were measured at the base line and at the end of 8th week.Results: After the treatment of 8 weeks, No statistically significant differences in PANSS scores of the two groups ( Pgt;0.05). The abdomen circumference after treatment groupincreased significantly (Plt;0.05), The control group body weight abdominal circumference,BMI values were increased significantly (Plt;0.05);, Comparison of body weight, abdominal circumference, BMI group between changes in the value of the value addedwas higher than in the control group (Plt;0.05).Conclusion: Combined with ziprasidone can obviously reduce the effects of quetiapine increase in female pati